RedHill Biopharma Ltd. (RDHL)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.52
- As of
Kresmion compiles this page from RDHL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
RedHill Biopharma Ltd. (RDHL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-13.
See the full RDHL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RDHL on one page. Preview it with sample data, then open it live with a free account.
Preview the RDHL dossierActive signals for RDHL
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +322% to RDHL (2026Q2)
- mediumEARNINGS_MISS
Q4-2021: Missed consensus by 48.5% - EPS $-500 vs $-336.6 estimate
- mediumEARNINGS_MISS
Q1-2022: Missed consensus by 27.9% - EPS $-300 vs $-234.6 estimate
- mediumEARNINGS_MISS
Q2-2022: Missed consensus by 553.6% - EPS $-200 vs $-30.6 estimate
- mediumEARNINGS_MISS
Q3-2021: Missed consensus by 137.2% - EPS $-500 vs $-210.8034 estimate
FREE, NO ACCOUNT
Every signal on RDHL, as it fires
You are seeing 5 of 8 signals recorded on RDHL since 2026-06-01.
The five above landed across 3 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RDHL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 757468301 · 2026Q2 | $55K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RDHL
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
RDHL against its peers
RDHL's operating margin of -181.7% ranks in the 39th percentile of 8 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-06-30 and 2025-06-30.
| Metric | RDHL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 8.0M USD | 828401 USD | 93 | 6 |
| Revenue YoY | 23.2% | 4.8% | 93 | 6 |
| Gross margin | 60.3% | 29.2% | 65 | 9 |
| Operating margin | -181.7% | -147.9% | 39 | 8 |
| Net margin | -102.8% | -189.8% | 65 | 9 |
| Return on equity | n/a | -68.9% | n/a | 6 |
| 1 year | n/a | -33.3% | n/a | 5 |
Peers (11): LVRLF, AKAN, BUDZ, IMCC, PRFX, GELS, CBIH, PCYN, SXTC, CPMD, BIOE. Left out: YCBD (period gap), PLSH (period gap), CTTH (period gap), SNOA (period gap), CVSI (period gap), APUS (period gap), INM (period gap), BTAI (period gap), CANN (period gap), SBFM (period gap), CABR (period gap), TRUFF (no annual filing), BFRI (period gap), CNTMF (no annual filing). Fiscal periods ending between 2024-06-30 and 2025-06-30. Every figure is one full fiscal year read from one annual filing (RDHL: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow RDHL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to RDHL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.